BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was -282.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 149.00K shares, a 61.79% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 608.00K shares, a 1092.16% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 801.00K shares, a 27.71% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.28M shares, a 58.08% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 3.04M shares, a 7.73% decline from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 3.30M shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2016 was 107.00K shares, a 90.43% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-12-31 | -282.00K shares derived: 10-K 12 month − 3 quarters · filed 2024-02-27 | 1.28M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 149.00K shares 10-Q · filed 2023-11-08 | |
| 2023-06-30 | 608.00K shares 10-Q · filed 2023-11-08 | |
| 2023-03-31 | 801.00K shares 10-Q · filed 2023-11-08 | |
| 2022-12-31 | 3.04M shares 10-K · filed 2023-02-27 | |
| 2022-09-30 | 390.00K shares 10-Q · filed 2023-11-08 | |
| 2022-06-30 | 51.00K shares 10-Q · filed 2023-11-08 | |
| 2022-03-31 | 1.11M shares 10-Q · filed 2023-11-08 | |
| 2021-12-31 | 3.30M shares 10-K · filed 2022-02-28 | |
| 2021-09-30 | 942.00K shares 10-Q · filed 2022-11-04 | |
| 2021-06-30 | 1.06M shares 10-Q · filed 2022-11-04 | |
| 2021-03-31 | 593.00K shares 10-Q · filed 2022-11-04 | |
| 2020-06-30 | 193.00K shares 10-Q · filed 2020-08-07 | |
| 2019-06-30 | 100.00K shares 10-Q · filed 2020-08-07 | |
| 2016-12-31 | 107.00K shares 10-K · filed 2017-02-27 | |
| 2015-12-31 | 16.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 1.12M shares 10-K · filed 2017-02-27 |
| 2015-09-30 | 169.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | 1.20M shares derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | 693.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 1.16M shares derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | 240.00K shares 10-Q · filed 2015-05-08 | |
| 2014-12-31 | 93.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 1.26M shares 10-K · filed 2017-02-27 |
| 2014-09-30 | 131.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2013-12-31 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | 563.00K shares 10-K · filed 2016-02-26 |
| 2013-09-30 | 255.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -125.00K shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | 203.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -346.00K shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | 104.00K shares 10-Q · filed 2013-05-09 | |
| 2012-12-31 | -687.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -350.00K shares 10-K · filed 2015-03-02 |
| 2012-09-30 | 34.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | |
| 2011-12-31 | 184.00K shares 10-K · filed 2014-03-10 | |
| 2010-12-31 | 240.00K shares 10-K · filed 2013-03-11 | |
| 2009-12-31 | 532.00K shares 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |